А - a а а a a а -a a a COVID-19. T а a a a a а а - -CVF P -A a Ta. Fa A. Ca a 1,2 , A G 3 , Ca G. Wa ⁴, J M C 3 1 A U,D a a H E M a а , Ea Pa D a Μ Μ a, U F S а а а (EPM/UNIFESP), S Pa , SP, B a Pa ^{2}C a I, Baa, DF, Ba ^{3}A I., I., CA, USA В ${}^{4}\mathrm{B}$ U , RI, USA А : Fα A. Ca a , MD, MS , P D D E a Ma , Da Μ , a Pa a, U a F E а Μ а S Pa R a P Т 781 13 ,04039-032 S Pa , SP B a E a : <u>a</u> . a <u>a</u> <u>a</u> <u>a</u> <u>;</u> <u>.</u> a <u>a</u> <u>a</u> <u>a</u> <u>.</u> : +55 61 996506111, Fa : +55 61 33464733 Т К -: COVID-19, SARS-C V-2, a a , a , а , А а Ba : W COVID-19 а a a а а а, а а a , a а а а а COVID-19. A a a а а а а a a a а а а, (HA) а а а (PCOS), а а a a а a a , a HA a (CAH) a a a (AGA), а а . T а а а a a а а а a a a a а а а COVID-19

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

а	,a a	а	HA a a	a a
a a.				
Maaa : F	a		a a	
COVID-19	a -	a a	a (PCR-S	SARS-C V-2)
a a	a -HA, HA	A, a HA	a	(HA-)
. Pa	а	a a	, 23	a ,44
a a a ,	28	, a		a a
a COVID-19 a	а	.Та	a	,
a 500 / a	a a	a,a	a	
400 / a a ,	a a 500	a	a a,	
0.2 / / a a	,a a	a	100 a	a.
Pa a	COVID-19	а,	a a a	a,a
a .				
R : I a , 270 a	,	195	, 67, a	-HA, HA,
а НА- ,	.Pa		a a (71	l.1%), a a
(67.0%), a a (48.1%)	, a a (37.4%	%),	(36.3%), a a	
a (34.1%), a (33.3%), a	(29.5%),	a (27.8%)	, a a
(24.8%), a a (24.1%)	а	(21.5%). Ea		(a)
$(1.0 \pm 0.2 day), ab$	dominal pain (1.	1±0.3);	a	a (1.1 ± 0.5),
a a	a (1.2 ± 0.5),	a a (1.2	\pm 0.5), dry coug	$gh~(1.2 \pm 0.5),$
a a (1.2 ± 0.4) , a a	(1.3 ± 0.5) a	a (1.3	<i>B</i> ± 0.5). T -	- a,
PCR, a a		a	a aa	a a
a HA-	a -H	A, HA, a	a	T a
a a a a		а	PCR-SARS	S-C V-2
a -	HA a HA. S	a		
a a a -	COVII	D-19. F	-HA a HA	a
a a a, a	a, ,	a , a	a	a. A a,
a a a a a		-HA a HA	A. N ::	a
a a a	COVID-19	a.		
C : A ,	a	COVID-19	a	a a a
a a	а		a	a
-, a -, a	(BMI)-, a	a - a	- a	
a , a	а	a -	а	a a

a a COVID-19 a . HA a a a a a , a . S a a a a A HA.

Background

COVID-19 a - a a a S A R a S C a 2 (SARS-C V-2). I a a a a a a, a a a a, a a a, a a a a (1-4).

a a а W а а а a , a a a a a a a a a а a a COVID-19, а а COVID-19 a a a а а , · ·, . Ma . a aa a a aa aa, а а (5).

B aa-a,aaa,aa<t

Y aa a a a , aaa,aa a a

(а	a a	а	а		а	a	а	a	а),
			а	а	, a	а					
	а			a	a				COVID-19		
	a		а	a a		a			(6-9).		

Aa aa

sine-quo-non а a a -P a C a R a (PCR) SARS-C V-2 (10,11). W COVID-19, а COVID-19 a, a a COVID-19 a a a a a . T a a a a COVID-19 a a a a а а a COVID-19, per se a a a a a COVID-19 a a . R a a COVID-19 a a a a a 10% a (12-14).

a invitroa aa aa SARS-S а C V-2 a a a COVID-19 (13), a а а а а a a, a a (13,14). H , a a COVID-19 a a a a , a a ,a aa a a.A , a a a a a (RCT) a a COVID-19 а ,a а a a (10-14).

Wa aaaaa aa aa COVID-19a a , a aaaaaa a.Taa a aaa, a COVID-19 aa aaa, a aaaaa.

А а а а , , COVID-19 a a а а а а а , a (15-23). O a / а а COVID-19 a а а а, (BMI), , i.e., а а а а (15-18). T a ,a а aaa, а а SARS-C V-2 а 2 (TMPRSS-2), a а а a a . A a а а а а a , a (AGA) a a COVID-19, а а а (AR), а а а (DHT) , a а а , , AGA a a , a а а

•

W COVID-19 a , а а а 2 a (T2DM), а а , a а , COVID-19 а а а а а .I a a a a a a a a AGA a а , , (HA), а а а (PCOS), a a (CAH) 21a aa a а а , а 11 aа а AGA, а HA, a , а а а а а а -HA а а а .

I а, а а а а , a (19-22). T а а а а а а a , a a a а а a a a а а COVID-19. N а а а а • , а а a ,a а а

Т а, а а, а а а а а а а COVID-19 а а а а, а а , a а a a a a

. A , a a a a , .

T, aa , a a a, a a a a a a.

А	a,A	, USA;	C a	SARS	-C V-2, R	,	S	a), a		
	SARS	S-C V-2									
	Ι		а	: 1	. C	CC	OVID-1	9		Р	CR-
SA	RS-C	V-2; 2. 18	a	а	a ; 3.	L	а		а		
		; 4. L	a 72		COVID-19)	а	(а	COVID-19	а
а	а); 4. N			a	24		а	a a	a
	; a	5. N					a		a.		

Design and methods

Pa a Ta 1. F a a а а а а а а a a , 23 a ,44 , 28 а а а HA, : 1. PCOS а а R a C a; 2. P CAH; 3. K а а а -, ; 4. H ; a 5. F a AGA. F a а -HA HA (), a а а а 100 / a (HA-S а) а а , (HA).

1. A a-С а а a ; 2. D / a ; 3. U А а а а (URTI) URTI-/ a ;4. а а а а Ga a (GI) ; 5. M / a а а ; 6. U ; 7. A а а.

Т	I Contraction of the second	а	а	, a	:		
1. A	a-A	а	a :	a a	a a		a,
,	-			,	-		а;
2. D	-	а	а	:a a	a a, a	a a,	a a,
	а	а	-	aa;			
3. URTI	-	a	а	:a a	a a		a,
,	-			,	-		а;

medRxiv preprint doi: https://doi.org/10.1101/2020.10.05.20206870; this version posted October 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . 4. GI а а :a a а, а a, а , а a a ; 5. M : а а а а 6. U а : а ; а а 7. A а. А 500 / a а а a a а , 400 / a 500 а, а, а а 0.2 / / a . T а a a а, а ,a / a a а а а , а - a а а а • •, , Ι D, С, . а а а а , a aa, , аа, , a , a а a a а а а . Pa a a : 1. T - -a a a а а а a); 2. T (, a); 3. T a (а a a а , a); 4. D a PCR-SARSа a a а a (C V-2 (a, PCR a a); 5. L -4, -3 -1, 0, 1, 2, 3, 7, 14, 21, 30 a 60 a , Da -7 а 0 (а а а 100 a a a ; 6. A) a Da 0, 3, 7, 14 a 30 (0 = a 100 = a a a a a a); 7. WHO COVID O а a - a а 0 S a ; 8. B a COVID-19 ; 9. D a aa, aa a, aa. F а aa aaa aa aa (:// . / 4 8/).

Statistical analysis

N aa	ANOVA (K	a-Wa) a		a aa ,
a	a	, a <i>post-hoc</i> a	D	a
a a	, 1	o <0.05. A a a	l	
XLSTAT (M	, USA).			

Aspect Baseline characteristics	Parameter
Baseline characteristics	!
	" #\$!%&'()!
	* \$+#,-!%.#)!
	/\$+#,-!%0)!
	1 2 3!%.#'0)!
	2 455+\$6!%&\$7'8()!486!,(97\$,(:67!%&\$7'8()!
Disease and treatment	!
timing	
-	;+0\$<-(<-5\$4-!%+8-\$5=4:!>\$-?\$\$8!>\$#+88+8#!(@!7&0A-(07!486!
	>\$#+88+8#!(@!7A\$B+@+B!-5\$4-0\$8-)!%64&7)!
	C954-+(8!(@!A(7+-+=\$!5-DEF!G " FG <e(h<i!%64&7)!< th=""></e(h<i!%64&7)!<>
	C954-+(8!(@!7&0A-(07!%8(-!+8B:96+8#!48(70+4!486!4#\$97+4)!
	%64&7)!
	C954-+(8!(@!7&0A-(07!%+8B:96+8#!48(70+4!486!4#\$97+4)!
	%64&7)!
Medical history	
E a	/ &A\$5-\$87+(8!
	2 & (B456+4:!+8045B-+(8!!
	G-5(.\$!
	E,5(8+B!,\$45-!04+:95\$!
	J+A+6!6+7(56\$57!
	; &A\$!I!6+4>\$-\$7!0\$::+-97!%; IC2)!
	D5\$<6+4>\$-\$7!
	C&7#:+B4\$0+4!%; IC 2 !K!A5\$<6+4>\$-\$7)!
	L>\$7+-&!
	"7-, 04! E - 5(0,0) + 7 500 + 6000 - 0 (0450 + 0.76476) (EL DON)
	$E_{5}(8+B!L>7-59B+==$!D9:0(845\&!C+7$47$!%ELDC)!$
	$E_{,5}(8+B!M+68\$\&!C+7\$47\$!\%EMC)!$
	J += \$5! 0 +> 5(7+7! (5!B+55, (7+7!)))
	2 4\\(5!6\$A5\$77+(8! ''80+\$-&!(5!480+\$-&<5\$:4-\$6!6+7(56\$57!
	"\$8-+(8!6\$@+B+\$8B&!486!,&A\$54B-+=\$!6+7(56\$57!% " C / C)!
	387(08+4!
	/ &A(-, &5(+6+70!
	"9-(+0.0988!6+7(56\$57!%48&)!
	E955\$8-!(5!A5\$=+(97!8(8<>5\$47-!8(8<-,&5(+6!B48B\$5!
	E955\$8-!(5!A5\$=+(97!>5\$47-!B48B\$5!
	E955\$8-!(5!A5\$=+(97!-,&5(+6!B48B\$5!
	2 \$8 (A497\$!
	P86(0\$-5+(7+7!!
	L-,\$5!6+7\$47\$7!%48&)!
Current medications	

Ca a a	1 -4 $>:$ (B. \$5!!
	"8#+(-\$87+8!B(8=\$5-\$5!+8,+>+-(57!%"EP+)!% <a5+:)!< td=""></a5+:)!<>
	"8#+(-\$87+8 <i!5\$b\$a-(5!>:(B.\$57!% "F1)!%<-48)!</i!5\$b\$a-(5!>
	J((A!6+95\$-+B7!%095(7\$0+6\$)!)
	;,+4Q+6\$!6+95\$-+B7!%,&65(B,:(5(-+4Q+6\$!%/E;R)\$!+864A40+6\$)!
	E4:B+90!B,488\$:!>:(B.\$57!%EE1)!%<6+A+8\$)!
	M<7A45+8#!6+95\$-+B7!%7A+5(8(:4B-(8\$)!
	$G-4+87!\%A+-4=4 \le 15(79=4 \le 14-(5=4 \le 1A54=4 \le 17+0=47-4+8)!$
	L-,\$5!:+A+6<:(?\$5+8#!4#\$8-7!%@+>54-\$7\$!\$Q\$-+0+>\$\$!DEGMT!
	+8,+>+-(57)!
	"7A+5+8!
	E:(A+6(#5\$:!
	* 45045+8!
	U4!@4B-(5!+8,+>+-(57!%4A+>4048\$!5+=45(04>48)!
	C+5\$B-!-,5(0>+8!+8,+>+-(57!%64>4#4-548)!
	/ \$A45+87!
	!
Da , ,a	1+#948+6\$7!%0\$-@(50+8)!
a - a	V:9B4#(8<:+.\$!A\$A+6\$!W!%VJDW)!5\$B\$A-(5!484:(#9\$7!%VJD<
	WF4)!%:+54<\$!7\$04<\$!69:4#:9-+6\$X!\$0\$84-+6\$)!
	G(6+90<#:9B(7\$!B(<-5487A(5-\$5!I!\GVJ;I)!+8,+>+-(57!
	%GVJ;I+)!%\$0A4<\$!64A4<\$!B484#:+0:(Q+8)!
	C+ <a\$a-&:!a\$a-+647\$!y!%cddy)!+8,+>+-(57!%CDDY+)!%=+:64<\$!7+-4<</a\$a-&:!a\$a-+647\$!y!%cddy)!+8,+>
	S!7404 <s!:+84#:+a-+8)!< td=""></s!:+84#:+a-+8)!<>
	G9:@(8&:95\$47!%#:+A+Q+6\$\$!#:+0\$A+5+6\$\$!#:+B4Q+6\$)!
	V:+-4Q(8\$!
	"B45>(7\$!
	3879:+8!
	L5:+7-4-!
H a a	J = (-, &5(0+8\$!%?+-, !(5!?+-, (9-!:+(-,&5(8+8\$)!
а	L54:!B(8-54B\$A-+=\$7!
	/ (50 (84:!5\$A:4B\$0\$8-!-, \$54A&!% / F;)!@(5!0\$8(A497\$!
	L-,\$5!, (50 (84:!5\$#+0 \$7!
	"5(04-47\$!+8,+>+-(57!%4847-5(Q(:\$X!:\$-5(Q(:\$)!
	G\$:\$B-+=\$!\$7-5(#\$8!5\$B\$A-(5!0(69:4-(57!\GPF 27)!
	!!
C a -a	/ &A8(-+B7!%Q(:A+6\$0\$!Q(A+B:(8\$\$!\$7Q(A+B:(8\$\$!540\$:-\$(8)!
	G\$:\$B-+=\$!7\$5(-(8+8!5\$9A-4.\$5!+8,+>+-(57!%GGF37)!%@:9(0\$-+8\$\$!
	6\$7) = 8:4040 + 8\$17\$5 - 54: + 8\$11\$7)B + -4: (A5405! = (5 - + (0\$ - + 8\$1))
	0:9=(040+8\$)!
	L-,\$5!48-+6\$A5\$7748-7!486!,90(5!7-4>+:+Q\$57!%>9A5(A+(8\$!
	-(A+5404-\$\$!-54Q(6(8\$\$!40+ (9!8(5-5+A-+:+8\$\$!-(A+5404-\$\$!</td
	(OB45>4 0 4Q\$A+8\$)!
	1 \$8Q(6+4Q\$A+8\$7!% J (54<\$!>5(0 4<\$!6+4<\$!B:(84Q\$A4 0 X!4:A54<\$!
	0+640(:40)!
	"-&A+B4:!48-+A7&B,(-+B7!%(:48Q4A+8\$\$!Z9\$-+4A+8\$\$!5+7A\$5+6(8\$\$!
	B:(Q4A+8\$\$!45+A+A54Q(:\$)!
	E\$8-54:!8\$5=(97!7&7-\$0!%E[G)!7-+09:48-7!%0\$-,&:@\$8+64-\$\$!
	:+76\$040@\$-40+8\$\$!0(64@+8+:)!
-	
0	•
O S	L 0 \$#4<\!%]!\#'64&)!
	L 0 \$#4<\!%]!\#'64&)! H+-4 0 +84!C!%]!\W\$^^^+9'64&)!

	29:-+=+-40+87!
Vaccine	2 9+-++0+0):
vaccine	: 1 EV!%:+@\$-+0\$)!
	380:9\$804!%+8!I^I)!
	$D8 = 0 (B(BB4:!W)!(5!I)! \%7+8B = 1^{3})!$
I :fogtalo	D0\$90(D(DD4.:W\!(J:1\!%/+0D\$:1``W)):
Lifestyle	
	E955\$8-!70(.+8#!%]!I!A4B.7'?\$\$.!486!]!W^!A4B.<&\$45)!
	F\$#9:45!A, &7+B4:!4B-+=+-&!%]!W_^0+8'?\$\$.\$!0(6\$54-\$<-(<
	=+#(5(97\$!)!!!2P;7\$!@(5!)!W&)!
Clinical characterization	P (/)
-	T a a a (a)
	D a (a)!
U	a\$=\$5!!
	ba\$=\$5+7,c!
	/\$464B,\$!
	G,(5-8\$77!(@!>5\$4-,!
	"8(70+4!
	'' #\$97+4!'!,&A\$5#\$97+4!'!6&7#\$97+4!!
	C+QQ+8\$77!
	* \$4.8\$77!
	a4-+#9\$!
	/ &A(5\$0+4!'!48(5\$0+4!
	;,(54B+B!A4+8!
	J (?\$5!>4B.!A4+8!
	C5&!\$&\$7!'!65&!0(9-,!'!7.+8!:\$7+(87!!
	15\$47-!A4+8!
U a a	[474:!B(8#\$7-+(8!(5!5,+8(55,\$4!
-	C5&!B(9#,!
	bG+897+-+7c!%7\$:@<5\$A(5-\$6!A\$5B\$A-+(8)!
	bG(5\$!-,5(4-c!%7\$:0<5\$A(5-\$6!A\$5B\$A-+(8)!
D -	2 &4:#+4!
	"5-,54:#+4!
	dAA\$5!>4B.!A4+8!
	E(8N98B-+=4:!, &A\$5\$0+4!)
	D5\$<(5>+-4:!A4+8!
Ga a (GI)	C+455,\$4!
-	[497\$47!
	H(0+-+8#!
~	">6(0+84:!(5!A\$:=+B!A4+8!
C a	"8(70+4<"#\$97+4!6(0+848B\$X!(5!
	C\$8#9\$<:+.\$!7&0A-(04-(:(#&!!'B:+8+B4:!A5\$7\$8-4-+(8X!(5!
	dF; 3<:+. \$!7&0A-(04-(:(#&!'!B:+8+B4:!A5\$7\$8-4-+(8X!(5!
	V3!+8@\$B++(8<:+.\$!7&0A-(04-(:(#&!'!B:+8+B4:!A5\$7\$8-4-+(8X!(5!
	2 + 0\$6X!(5!
	d 87A\$B+@+BX!(5!
	"7& 0 A-(0 4-+B!
Treatment	
	/ &65(0&B,:(5(Z9+8\$!Y^^0#'64&!@(5!^_!64&7\$!(5!
$("Q+-,5(0\&B+8!_^0)\#'64\&!@(5!)$	$[+-40(048+6\$!_^0 0 #!13C!@(5!^e!64&7\$!(5!)]]$
^_!64&7!K)!!	$3=\$50\$B+8!^{f}I0\#'.\#'64\&!!(5!^{!}64\&7!)$
	5=5505B-+8!^110# .# 64&!@(5!^\!64&7! K' !</th
	$K < !! GA+5(8(:4B-(8$!W^{0}) #!13C!@(5!W_!64&7$!(5!!))$
	$C9-47-55+65!^{f}=0\#'64\&!98-+:!B955!$
	<u> しアーキアー</u> ゆJTUゆに 1_U# U4&!70-T.!D7Jゆ!

A a a	U4!04B-(5!+8,+>+-(57!
(a a a	* 45045+8!
)	P8(04A45+8!
)	"B\$-&:74:+B&:+B!4B+6!% "G")!
	V:9B(B(5-+B(+67!%0\$-,&:A5\$68+7(:(8\$\$!6\$040\$-,47(8\$\$!
	A5\$68+7(8\$\$!A5\$68+7(:(8\$)!
	15(0,\$0+8\$!
	[<4B\$-&:B&7-\$+8\$!
	E(:B,+B+8\$!
	$H_{-4}0+8!E!$ $(84:16(7))$
	R+8B!%466+++(84:!6(7\$\$!+0!4:5\$46&!986\$5!97\$)!
	H+-40+8!C!%466+-+(84:!6(7\$\$!+@!4:5\$46&!986\$5!97\$)!
Outcomes (Day 0 =	!
beginning of treatment)	
WHO COVID O a	C4&!^!
0	C4&!`!
(S a 1-5)	C4&!WY!
(5 u 1 5)	C4&!\^!
	C4&!e^!
L a a	C4&!^!
a $(0-100; 0 =$	C4&!\!
; 100 =	C4&!`!
	C4&!WY!
a)	C4&!\^!
S	C4&!<`!-(! <y!< th=""></y!<>
(0-100;0=a	C4&!<\!-(! <w!< th=""></w!<>
; 100 =	C4&!^!
, 100	C4&!W!
`	C4&!I!
)	C4&!\!
	C4&!`!
	C4&!WY!
	C4&!IW!
	C4&!\^!
	C4&!e^!
T a CT a	C4&!^!
	C4&!`!
(% a)	C4&!!! C4&!WY!
	C4&!\^!
D : .	<u>!</u>
Disease progression	!
outcomes	
	15\$7B+4!ELH3C <wt!f\$7a+54-(5&!g\$=\$5+-&!gb4:\$!%^<y)!< th=""></wt!f\$7a+54-(5&!g\$=\$5+-&!gb4:\$!%^<y)!<>
	/(7A+-4:+Q4-+(8!
	38-\$87+=\$!E45\$!d8+-!%3Ed)!
	2 \$B, 48+B4: $!=$ \$8-+: 4-+ (8!
	[(5465\$84:+8\$'6(A40+8\$!
	C\$4-,!
	··· ,·

Ta 6 15	5 a aa	a aa		а	a a	а
(-HA, HA	a HA-), a a a	a	а	. Ta	2 5
a a	а	aa , Ta	6	8	CO	VID-19
a , Ta	9 a 10		a a	а		
COVID-19, a Ta	11 15	COVID-19	а			

Patients characteri ation

		I a, 270) a		COVID-1	9	. O , 195, 67,	
	а		-HA	A, HA, a	a HA-	. T	a a	
	a	a a a	а		a.			
		Ba	a a	a	Та	2. HA a	a	
		, ,a	а	a ·	-HA.			
	!							
	Та	2. Ba	a a					
Baseline characteris	tics	Overall females (n = 270)	Non-HA females (n = 195)		HA females (n = 67)	Spironolacto ne Users () (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Age (y/o)!)!		40.5 ±11.5!	42.5 ±11.6)	35.2 ± 9.5	37.0 ± 7.1	<i>40.6 ± 11.5</i> !	''!#\$ ### %!
Height (m)		1.63 ± 0.06!)	,	,		

Comorbidities	Overall	Non-HA	HA females	Spironolactone	Non-spiro	p-value
	females	females	(n = 67)	Users ()	(non-HA + HA)	(overall)
	(n = 270)	(n = 195)		(n = 8)	(n = 262)	
Hypertension!	38 (14.1%)!	24 (12.3%)	12 (17.9%)	2 (25.0%)	'&!+% '\$2!	#\$&2!+/03.!
Myocardial	1 (0.4%)!	1 (0.5%)!		0	%!+#\$)!	#\$,,!+/03.!
infarction						
Stroke	1 (0.4%)!	1 (0.5%)		0	%!+ # \$)!	#\$,,!+/03.!
Chronic Heart	0!	0			#!	/01!
Failure (CHD)						
Lipid disorders	63 (23.3%)!	43 (22.1%)	17 (25.4%)	3 (37.5%)	&#!+((\$,!</td><td>#\$4(!+/03.!</td></tr><tr><td>Type 2 diabetes</td><td>20 (7.4%)!</td><td>10 (5.1%)</td><td>8 (11.9%)</td><td>0</td><td>%2!+&\$,!</td><td>#\$)2!+/03.!</td></tr><tr><td>mellitus !</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>(T2DM)</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Pre-diabetes</td><td>21 (7.8%)!</td><td>11 (5.6%)</td><td>9 (13.4%)</td><td>2 (25.0%)</td><td>(#!+4\$&!</td><td>#\$&(!+/03.</td></tr><tr><td>Dysglycemia !</td><td>41 (15.3%)!</td><td>21 (10.8%)</td><td>17 (25.4%)</td><td>1 (12.5%)</td><td>'2!+%)\$*!</td><td>#\$4,!+/03.</td></tr><tr><td>(T2DM + pre-</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>diabetes)!</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Obesity</td><td>52 (19.3%)!</td><td>32 (16.4%)</td><td>18 (26.8%)</td><td>2 (25.0%)</td><td>*#!+%,\$%!</td><td>#\$)(!+/03.</td></tr><tr><td>Asthma</td><td>16 (5.9%)!</td><td>12 (6.2%)</td><td>4 (6.0%)</td><td>0</td><td>%&!+&\$%!</td><td>#\$,)!+/03.</td></tr><tr><td>Major depression</td><td>15 (5.6%)!</td><td>11 (5.6%)</td><td>4 (6.0%)</td><td>0</td><td>%*!+*\$4!</td><td>#\$,&!+/03.</td></tr><tr><td>Anxiety-related</td><td>41 (15.2%)!</td><td>22 (11.3%)</td><td>16 (23.9%)</td><td>3 (37.5%)</td><td>'2!+%)\$*!</td><td>#\$%4!+/03.</td></tr><tr><td>disorders</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Attention deficiency</td><td>14 (5.2%)!</td><td>18 (9.4%)</td><td>7 (10.4%)</td><td>1 (12.5%)</td><td>% ' !+*\$#!</td><td>#\$&'!+/03.</td></tr><tr><td>and hyperactive</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>disorders (ADHD)</td><td></td><td></td><td></td><td>1 (10 50 ()</td><td></td><td>UR 4 1 /02</td></tr><tr><td>Insomnia</td><td>15 (5.6%)!</td><td>8 (4.1%)</td><td>6 (9.0%)</td><td>1 (12.5%)</td><td>%)!+*\$'!</td><td>#\$4,!+/03.</td></tr><tr><td>Hypothyroidism</td><td>54 (20.0%)!</td><td>38 (19.5%)</td><td>14 (20.9%)</td><td>2 (25.0%)</td><td>*(!+%,\$2!</td><td>#\$,&!+/03.</td></tr><tr><td>Autoimmune</td><td>10 (3.7%)</td><td>9(4.6%)</td><td>1 (1.5%)</td><td>0</td><td>%#!+'\$2!</td><td>#\$'2!+/03.!</td></tr><tr><td>disorders</td><td>65 (0 4 10 ())</td><td></td><td>0 (11 00 ()</td><td>1 (10 50 ()</td><td>0.51.7.565</td><td>1100/111-102</td></tr><tr><td>Menopause</td><td>65 (24.1%)!</td><td>56 (28.7%)*</td><td>8 (11.9%)</td><td>1 (12.5%)</td><td>&)!+()\$)!</td><td>#\$%#!+/03.</td></tr><tr><td>Endometriosis</td><td>29 (10.4%)!</td><td>17 (8.7%)</td><td>11 (16.4%)</td><td>1 (12.5%)</td><td>(2!+%#\$4!</td><td>#\$&)!+/03.</td></tr><tr><td>Breast cancer</td><td>Y!%Wf_g)!</td><td>3 (1.5%)</td><td>1 (1.5%)</td><td>0</td><td>)!+%\$*!</td><td>#\$,,!+/03.!</td></tr></tbody></table>	


	Та	4		а		а		а	a	a	. M	
a	a	а				a	а			HA	a	-HA
a	. N				а	, a	а	а,		a		а
a						. Wa	а,					а
a			а	а	. T	а	l	а	a		а	

BCG,	a a		а	а	, a	a	а
а	a (Ta	5).					

Current	Overall	Non-HA	HA	Spironolactone	Non-spiro	p-value
medications	females	females	females	Users ()	(non-HA +	(overall)
	(n = 270)	(n = 195)	(n = 67)	(n = 8)	$\dot{H}A$) (n = 262)	· · · ·
Beta-blocker !	3 (1.1%)!	3 (1.5%)	0	0	'!+%\$%!	5!#\$,!+/03.!
Angiotensin converter inhibitors (ACEi)	8 (3.0%)!	5 (2.6%)!	2 (3.0%)	1 (12.5%)	4!+(\$4!	5!#\$,!+/03.!
Angiotensin-2 receptor blockers (ARB)	32 (11.8%)!	19 (9.7%)	12 (17.9%)	1 (12.5%)	'%!+%%\$2!	#\$&%!+/03.!
Loop diuretics	3 (1.1%)!	2 (1.0%)	0	1 (12.5%)	(!+#\$2!	/01!
Thiazide diuretics	10 (3.7%)!	8 (4.1%)	2(3.0%)	0	%#!+'\$2!	5!#\$,!+/03.!
Calcium channel blockers (CCB)	16 (5.9%)!	10 (5.1%)	6 (8.9%)	0	%&!+&\$%!	#\$2&!+/03.!
DIOCKCI'S (CCD)	!				!	
Statins!	51 (18.9%)!	33 (16.9%)	17 (25.4%)	1 (12.5%)	*#!+%,\$%!	#\$*&!+/03.
Aspirin	1 (0.4%)!	1 (0			%!+#\$)!	/01

Combined therapy (E+P) (for	29 (10.7%)	24 (12.3%)	5 (7.5%)	0	(,!+%%\$%!	#\$4'!+/03.!
menopause)						
Oral contraceptives	36 (13.3%)	17 (8.7%)*	19 (28.4%)	0	'&!+% '\$4!	#\$#)*!
Other hormonal regimens	0	0	0	0	#!	/01!
Aromatase inhibitors (anastrozole; letrozole) or Selective	3 (1.1%)	1 (0.5%)	2 (3.0%)	0	'!+%\$%!	#\$2*!+/03.!
estrogen receptor modulators (SERMs)						
Hypnotics	19 (7.0%)	10 (5.1%)	8 (11.9%)	1 (12.5%)	%2!+&\$,!	#\$&2!+/03.!
Selective serotonin reuptaker inhibitors (SSRIs)	43 (15.9%)	27 (13.8%)	13 (19.4%)	3 (37.5%))#!+%*\$'!	#\$44!+/03.!
Other antidepressants and humor stabilizers	27 (10.0%)	15 (7.7%)	11 (16.4%)	1 (12.5%)	(&!+%#\$#!	#\$*4!+/03.!
Benzodiazepines	3 (1.1%)	2 (1.0%)	1 (1.4%)	0	'!+%\$%!	#\$,,!!+/03.!
Atypical antipsychotics Central nervo	7 (2.6%)	4 (2.0%)	3 (4.5%)	0	4!+(\$4!	#\$,%!+/03.!

COVID-19 clinical presentation



a 20%aa
$$(15.9\%)$$
, -a a(12.6%), aa $a(10.4\%)$,aa (8.1%) ,a a(12.6%), aa $a(10.4\%)$,aa (8.1%) ,a a(12.6%), aa $a(7.7\%)$,(6.7%),a (5.9%) ,(1.1%), aa $a(5.2\%)$,a - a a (3.5%) ,(2.2%) a

COVID-19 a , a a
: 1. Ea (< 2.0 a ; a): (1.0
$$\pm$$

0.2), abdominal pain (1.1 \pm 0.3); a (1.2 \pm 0.5), dry cough (1.2 \pm 0.5), a a
a (1.2 \pm 0.5), a a (1.2 \pm 0.5), dry cough (1.2 \pm 0.5), a (1.2 \pm 0.4),
a a (1.3 \pm 0.5), a (1.3 \pm 0.5), (1.3 \pm 0.5), a (1.3 \pm 0.5),
a (1.4 \pm 0.7), - a a (1.4 \pm 0.6), sore throat (1.4 \pm 0.7), (1.5
 \pm 0.6, (1.5 \pm 0.6), a a a (1.5 \pm 0.6) and diarrhea (1.5 \pm 0.8); a 2. La
(> 2.0 a) upper back pain (2.0 \pm 0.8); lower
back pain (2.1 \pm 0.7); a a (2.5 \pm 1.0); a a (3.4 \pm 1.3), a (3.4 \pm 1.3),
a (3.8 \pm 1.2).

COVID-19 a Dа а (1.9 ± 1.0) , a a a (1.8 ± 0.7) , a a (1.7 ± 0.9) , а, $(2.4 \pm 1.2),$ a (2.5 ± 1.6) , a $(2.7 \pm$ $(2.3 \pm 0.8);$ 1.4) a - a a (2.8 ± 1.3) ; a a $(3 \ 5 \ a)$, a a (3.0 ± 2.4) , a (3.2 ± 1.5) , a (3.3 ± 1.4) , a (3.3 ± 1.4) a (3.6 ± 1.8) , a a (4.3 ± 2.1) , a a 1.5), a a (4.7 ± 2.5) , a (4.8 ± 2.8) , a a (4.9 ± 2.6) ; a (>5 a), (5.4 ± 3.5) a (5.5 ± 1.9) , а $(5.7 \pm 3.5),$ $(6.0 \pm 2.6), dry eyes (6.2 \pm 2.1), a = a (7.0 \pm 5.7), dry$ a a mouth (7.0 \pm 0.0), a (7.2 \pm 4.9) and a a (7.9 \pm 6.2).

S a a a : , - -a a a , a a a, a a , а, а, а , , a,a а, а a, a a, a aa, - aa,a . A HA а а a a a -HA a (a), a a а а а .

	А	a a	a	а	a	а		а		. F	-HA
а	HA	а	а		а	a, a	a,		, a	, a	а
	a. A	A a,	а	а	а	a a			-HA	a HA.	
Т	a	a a	а		-]	HA	a	а	•		

!

Clinical manifestations	Overall females (n = 270)		Non-HA females (n = 195)	HA females (n = 67)	Spironolactone Users () (n = 8)	Non-spiro (non- HA + HA) (n = 262)	p-value! (overall)
Fever	!	_///	(1 1)0)	(11 07)	(11 0)	!	!
!							
D5\$7\$8B\$!%g))!	!		(n/s (p=0.32) vs HA) (n/s (p=0.64) vs spiro)	(n/s(p=0.41) vs spiro)	0 (n/s(p=0.57) vs no-spiro)	31 (11.8%)	0.52
;+0\$!-(! 4AA\$4548B\$!%64&7))!	±	!	<u>±</u> (n/s (p=0.19) vs HA) (n/a vs spiro)	± (n/a vs spiro)	- (n/a)	1.5 ±	/a
C954-+(8!%64&7))!	\pm	!	$\frac{\pm}{(n/s \ (p=0.48) \ vs \ HA)}$ (n/a vs spiro)	$\frac{\pm}{(n/a \ vs \ spiro)}$	- (n/a)	(\$(!± !	/01!
"Feverish" !	!		(!	!
D5\$7\$8B\$!% g))!		!	(n/s (p=0.12) vs HA) (n/s (p=0.38) vs spiro)	(n/s(p=0.13) vs spiro)	0 ((n/s(p=0.26) vs no-spiro)	&%!+('\$'!	#\$%&!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	<u>±</u>	!	$\frac{\pm}{(n/s \ (p=0.87) \ vs \ HA)}$ (n/a vs spiro)	<u>+</u> (n/a vs spiro)	0 (n/a vs no-spiro)	%\$)!± !	/01!
C954-+(8!%64&7))!	<u>±</u>	!	$\frac{\pm}{(n/s \ (p=0.76) \ vs \ HA)}$ (n/a vs spiro)	± (n/a vs spiro)	0 (n/a vs no-spiro)	(\$)!± !	/01!
Nasal congestion or rhinorrhea !	!		(!	!
D5\$7\$8B\$!%g))!		!	(n/s (p=0.33) vs HA) (n/s (p=0.73) vs spiro)	(n/s(p=0.48) vs spiro)	((n/s(p=0.65) vs no-spiro)	,#!+')\$*!	#\$*&!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	<u>+</u>	!	$\frac{\pm}{(n/s \ (p=0.69) \ vs \ HA)}$ (n/a vs spiro)	± ((n/a vs spiro)	± (n/a vs no- spiro)	± !	/01!
C954-+(8!%64&7))!	<u></u>	!	$\frac{\pm}{(n/s \ (p=0.72) \ vs \ HA)}$ (n/a vs spiro)	± (n/a vs spiro)	<u>+</u> (n/a vs no-spiro)	'\$&!± !	/01!
Headache !	!		(ind is spiro)			!	!
D5\$7\$8B\$!% g))!		!	(n/s (p=0.12) vs HA) (n/s (p=0.33) vs spiro)	(n/s(p=0.13) vs spiro)	((n/s(p=0.15) vs no-spiro)	%(2!+)2\$2!	#\$%&!
;+0\$!-(! 4AA\$4548B\$!%64&7))!			$\frac{\pm}{(n/s \ (p=0.10) \ vs \ HA)}$ (n/a vs spiro)	± (n/a vs spiro)	<u>+</u> (n/a vs no-spiro)	%\$(!± !	/01!
C954-+(8!%64&7)	\pm	!	<u>+</u>	<u>+</u>	<u>±</u>	*\$2!± !	/01!

)!				(n/s (p=0.63) vs HA) (n/a vs spiro)	(n/a vs spiro)	(n/a vs no-spiro)		
Shortness of breath !	!						!	!
D5\$7\$8B\$!%g))!			!	(n/s (p=0.72) vs HA) (n/s (p=0.64) vs spiro)	(n/s(p=0.68) vs spiro)	((n/s(p=0.79) vs no-spiro)	%&!+&\$%!	#\$2*!
;+0\$!-(! 4AA\$4548B\$!%64&7))!		±	!	$\frac{\pm}{(n/s \ (p=0.28) \ vs \ HA)}$ (n/a vs no-spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	'\$4 ± ‼	/01!
C954-+(8!%64&7))!		<u>+</u>	!	<u>±</u> (n/s (p=0.72) vs HA) (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	(\$* ± !	/01!
Anosmia !	!						!	!
D5\$7\$8B\$!% g))!			!	(p = 0.025 vs HA) (p = 0.0008 vs spiro)	(p = 0.0007 vs AGA-5ARi)	(p = 0.0036 vs no-5ARi)	%,%!+4(\$,!	#\$##%!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	!	<u></u>		± (p=0.0009 vs HA) (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	'\$)! <i>±</i> !	''!#\$ ### %
C954-+(8!%64&7))!		<u></u>	!	<u>±</u> (n/s(p=0.63) vs HA) (n/a vs spiro)	± (n/a vs spiro)	3 (n/a vs no-spiro)	4\$,! <i>±</i> !	'' !#\$###%
Ageusia !	!			(!	!
D5\$7\$8B\$!% g))!	!			(p=0.015 vs HA) (p=0.014 vs spiro)	(p=0.001 vs spiro)	(p=0.007 vs no-5ARi)	%2#!+&,\$4!	#\$##%'!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	!	±		<u>±</u> (p=0.011 vs HA) (n/a vs spiro)	± (n/a vs spiro)	1 (n/a vs no-spiro)	'\$*! <i>±</i> !	/01!
C954-+(8!%64&7))!		±	!	<u>+</u> (p=0.045 vs HA) (n/a vs spiro)	<u>+</u> (n/a vs spiro)	(n/a vs no-spiro)	4\$%! ± !	/01!


Dry cough !

)!			(n/s(p=0.27) vs spiro)				
;+0\$!-(! 4AA\$4548B\$!%64&7))!	<u>+</u>	!	<u>±</u> (n/s(p=0.17) vs HA) (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	%\$'±!	/01!
C954-+(8!%64&7))!	±	!	<u>+</u> (n/s(p=0.99) vs HA) (n/a vs spiro)	<u>+</u> (n/a vs spiro)	(n/a vs no-spiro))\$2 ± !	/01!
Thoracic pain						!	!
D5\$7\$8B\$!%g))!		!	(n/s(p=0.093) vs HA) (n/s(p=0.099) vs spiro)	(n/s(p=0.22) vs spiro)	0 (n/s(p=0.24) vs no-spiro)	&4!+(*\$&!	#\$%%!+/03.!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	<u>+</u>	!	$\frac{\pm}{(n/s(p=0.61) vs HA)}$ (n/a vs spiro)	<u>+</u> (n/a vs spiro)	(n/a vs no-spiro)	(\$& ± !	/01!
C954-+(8!%64&7))!	±	!	\pm (n/s(p=0.31) vs HA) (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro))\$4 ± !	/01!
Upper back pain						!	!
D5\$7\$8B\$!% g))!		!	(n/s(p=0.15) vs HA) (n/s (p=0.71) vs spiro)	(n/s (p=0.37 vs spiro)	(n/s (p=0.61 vs no-spiro)	(2!+%#\$4!	#\$'%!+/03.!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	<u>+</u>	!	± (p=0.006 vs HA) (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	(\$# ± !	/01!
C954-+(8!%64&7))!	<u>+</u>	!	\pm (n/s (p=0.33) vs HA) (n/a vs spiro)	<u>+</u> (n/a vs spiro)	(n/a vs no-spiro))\$'±!	/01!
Lower back pain						!	!
D5\$7\$8B\$!%g))!		!	(n/s (p=0.99) vs HA) (n/s(p=0.81) vs spiro)	(n/s (p=0.78) vs spiro)	0 (n/s (p=0.80) vs no-spiro)	%)!+*\$'!	#\$,&!+/03.!
;+0\$!-(! 4AA\$4548B\$!%64&7))!	<u>+</u>	!	$\frac{\pm}{(n/a vs HA)}$ (n/a vs spiro)	$\frac{\pm}{(n/a \ vs \ spiro)}$	(n/a vs no-spiro)	(± !	/01!
C954-+(8!%64&7))!	<u></u>	!	± (n/a vs HA) (n/a vs spiro)	$\frac{\pm}{(n/a \ vs \ spiro)}$	(n/a vs no-spiro))\$'±!	/01!
Diarrhea ! D5\$7\$8B\$!%g))!		!	(n/s (p=0.15) vs HA)			!	!

D5\$7\$8B\$!%g)			!	1			(!+#\$2!	%\$#!+/03.!
)!			•	(n/a vs HA) (n/a vs spiro)	(n/a vs spiro)	(n/a vs no-spiro)	(//////////////////////////////////////
;+0\$!-(! 4AA\$4548B\$!%64&7))!		<u>+</u>	!	l (n/a vs HA) (n/a vs spiro)	3 (n/a vs spiro)	(n/a vs no-spiro)	+%6'.!	/01!
C954-+(8!%64&7))!		<u>+</u>	!	(n/a vs HA) (n/a vs spiro)	(n/a vs spiro)	(n/a vs no-spiro)	+%6'.!	/01!
Abdominal pain	!						!	!
D5\$7\$8B\$!%g))!			!	(n/s (p=0.52) vs HA) (n/s (p=0.75) vs spiro)	(n/s(p=0.58) vs spiro)	(n/s (p=0.70) vs no-spiro)	(%!+2\$#!	#\$4*!
;+0\$!-(! 4AA\$4548B\$!%64&7))!		±	!	$\frac{\pm}{(n/s \ (p=1.0) \ vs \ HA)}$ (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	%\$% ± !	/01!
C954-+(8!%64&7))!		±	!	\pm (n/s (p=0.23) vs HA) (n/a vs spiro)	$\frac{\pm}{(n/a \ vs \ spiro)}$	(n/a vs no-spiro)	%\$2 ± !	/01!
Conjunctival hyperemia !	!						!	!
D5\$7\$8B\$!%g))!			!	(n/s(p=0.071) vs HA) (n/s (p=0.82) vs spiro)	(n/s (p=0.37) vs spiro)	(n/s (p=0.69) vs no-spiro)	((!+2\$)!	#\$%2!
;+0\$!-(! 4AA\$4548B\$!%64&7))!		±	!	<u>±</u> (n/s (p=0.88) vs HA) (n/a vs spiro)	$\frac{\pm}{(n/a vs spiro)}$	(n/a vs no-spiro)	%\$% ± !	/01!
C954-+(8!%64&7))!		±	!	\pm (n/s (p=0.54) vs HA) (n/a vs spiro)	$\frac{\pm}{(n/a \ vs \ spiro)}$	(n/a vs vs no-spiro)	*\$# ± !	/01!
Pre-orbital pain	!			, , ,			!	!
D5\$7\$8B\$!%g))!			!	(n/s (p=0.57) vs HA) (n/s (p=0.57) vs spiro)	(n/s (p=0.78) vs spiro)	(n/s (p=0.53) vs no-spiro)	')!+%'\$#!	#\$4#!+/03.
;+0\$!-(! 4AA\$4548B\$!%64&7))!		±	!	$\frac{\pm}{(n/s \ (p=0.27) \ vs \ HA)}$ (n/a vs spiro)	$\frac{\pm}{(n/a \ vs \ spiro)}$	(n/a vs no-spiro)	%\$) ± !	/01!
C954-+(8!%64&7))!		<u>+</u>	!	<u>+</u> (p=0.016) vs HA) (n/a vs spiro)	± (n/a vs spiro)	(n/a vs no-spiro)	(\$2 ± !	/01!
Dry eyes	!			(*** ** * F * *)			!	!
D5\$7\$8B\$!%g))!			!	(n/s (p=0.99) vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)	&!+(\$'!	#\$,2!+/03.
;+0\$!-(! 4AA\$4548B\$!%64&7))!		±	!	$\frac{\pm}{(n/a \text{ vs } HA)}$ (n/a vs spiro)	(n/a vs spiro)	(n/a vs no-spiro)	%\$) ± !	/01!

)!

COVID-19 course and outcomes



;4>:\$!W^f!ELH3C <wt!b:+8+b4:< th=""><th>(9-B(0\$7f</th></wt!b:+8+b4:<>	(9-B(0\$7f

Clinical	Overall	Non-HA	HA females	Spironolactone	Non-spiro	p-value
clustering	females	females	(n = 67)	Users ()	(non-HA +	(overall)
	(n = 270)	(n = 195)		(n = 8)	HA) $(n = 262)$	
Time-to-treat! !	3.0 ± 1.8!	3.0 ± 1.9 (n/s (p=0.11) vs HA) (p<0.007 vs spiro)	3.4 ± 1.4 (p=0.0001 vs spiro)	0.5 ± 1.1 (Median = 0; 95%CI = 0.7) (p=0.0003 vs no-spiro) (p = 0.0028 vs no-spiro after adjustment for symptomatic	3.1 ±1.8 !	#\$###)!
Duration of positive rtPCR (days)! !	13.9 ± 6.1!	13.5 ± 5.7 (p=0.033 vs vs HA) (p=0.025 vs spiro)	15.7 ± 6.7 (p=0.0005 vs spiro))	patients only) 8.7 ± 3.0 (p=0.015 vs no-spiro) (p = 0.015 vs no-spiro after adjustment for symptomatic patients only)	%)\$#!±6.1!	#\$##*4!
Remission not including anosmia (days)!	5.8 ± 4.7!	5.5 \pm 4.7 (p=0.0003 vs vs HA) (p=0.0008 vs spiro) (p = 0.015 vs spiro after adjustment for symptomatic patients only)	7.2 \pm 4.5 (p<0.0001 vs spiro)) (p=0.0002 vs spiro after adjustment for only symptomatic patients)	1.4 ± 1.4 (Median = 1; 95%CI = 1.0) (p=0.0003 vs no-spiro) (p = 0.0046 vs vs no-spiro after adjustment for symptomatic patients only)	&\$#!±4.7!	"!#\$####%! (p < 0.0001 after adjustment for only symptomatic patients)!
Remission including anosmia (days)!	9.6 ± 7.3!	9.0 ± 7.1 (p=0.0001 vs HA) (p=0.0004 vs spiro) (p=0.0046 vs spiro after adjustment for symptomatic patients only)	12.4 \pm 7.0 (p<0.0001 vs spiro)) (p<0.0001 vs spiro after adjustment for only symptomatic patients)	$1.7 \pm 2.0 \text{ (Median} =$ 1; 95%CI = 0.3) (p=0.0001 vs no-spiro) (p = 0.0013 vs no-spiro after adjustment for symptomatic patients only)	,\$,! <i>±7.3</i> !	"!#\$####%! (<0.0001 after adjustment for only symptomatic patients)!

HA = a c; / = - ca; /a = -a cab

Clinical evolution	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spironolactone Users () (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value (overall)
Days -7 to -4!	\pm	\pm	\pm	\pm	4,\$&!±	#\$'*!+/03.!
!	!					
		(n/s(p=0.41) vs HA) (n/s (p=0.21) vs spiro)	(n/s (p=0.34) vs spiro)	(n/s(p=0.23) vs no-spiro)	!	
Days -3 to -1!	\pm	\pm	<u>+</u>	\pm	'(\$,! <u>+</u>	#\$#%)!
	!	(n/s (p=0.41) vs AGA vs HA) (p=0.007 vs spiro)	(p=0.003 vs spiro)	(p=0.005 vs no-spiro)	!	
Day 0!	±	±	±	\pm	'%\$(!±	#\$#4(!+/03.
	!	((p=0.045) vs AGA vs HA) (n/s (p=0.29) vs spiro)	(n/s (p=0.16) vs spiro)	(n/s (p=0.25) vs no-spiro)	!	
Day 1!	\pm	±	\pm	\pm	±	#\$###2!
	!	(p=0.0002 vs HA) (/n/s (p<0.30) vs spiro)	(n/s (p=0.12)) vs spiro)	(n/s (p=0.23) vs no-spiro)	!	
Day 2!	±	±	\pm	±	4)\$2! <i>±</i>	"!#\$###%!
		(p<0.0001 vs HA) (p=0.0051) vs spiro)	(p=0.0007 vs spiro)	(p=0.044 vs no-spiro)	!	
Day 3!	<u>±</u>	±	<u>+</u>		±	"!#\$###%!
	!	(p=0.0007 vs HA) (p<0.0001 vs spiro)	(p=0.0001 vs spiro)	(p=0.0016 vs no-spiro)	!	
Day 7!	\pm	\pm	\pm	\pm	, '\$2! <i>±</i>	#\$#%2!
	!	(p=0.023 vs HA)	(p=0.023 vs spiro)	(n/s (p=0.094) vs no-spiro)	!	
Day 14!	±	$\frac{(n/s \ (p=0.15) \ vs \ spiro)}{\pm}$	±	±	,2\$)!±	#\$&4!+/03.!
		(n/s(p=0.45) vs HA)	(n/s (p=0.49) vs spiro)	(n/s (p=0.62) vs no-spiro)	!	
Day 21!	±	(n/s (p=0.67) vs spiro) ±	±	±	, ,\$)!±	%\$#!+/03.!
		(n/s vs HA)	(n/s vs spiro)	(n/s vs no-spiro)	!	
Day 30!	±	(n/s vs spiro) ±	±	±	,,\$2!±	%\$#!+/03.!
		(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)	!	

Day 60!	<u>+</u>		\pm		\pm		<u>+</u>	%	##\$#! <i>±</i>	%\$#!+/03.!
			vs HA) vs spiro)	(1	n/s vs spiro)		(n/s vs no-spiro)		!	
	HA = a	c; / =	- ca ; /a	a = -a	a cab;	CI = c	c a			
	А	Ta 12,			W	Ha C) a a	(WHO) COVID	
	O a O			а	, HA	a	a	a		
	a -HA	Aa HA-		Da	0 a	7, a	a	a a	Da 14.	
	Ν	а	a S	3	5		а.			
	Т	a a			a a			Та	13. N	
		а	a a			ä	a a	. C	, HA	
		a			а	ı	-HA a	HA-	а	
	(=0.004 a)	0.028,),		a		а	а	(Da 0).	
	T a	а		а	(Da 3	, 7, 14 a	a 30). E		-HA	
	(a	a a), Da 3 a		a		a	Da	0.	


;4>:\$!WI. WHO COVID-19 O a O

WHO COVID Ordinal Outcomes	Overall females (n = 270)	Non-HA females (n = 195)	HA females (n = 67)	Spironolactone Users () (n = 8)	Non-spiro (non-HA + HA) (n = 262)	p-value! (overall)
Day 0	!	(p=0.028 vs HA) (n/s((p=0.15) vs spiro)	(p=0.028 vs spiro)	(n/s((p=0.098) vs no-spiro))		0.002 !
G-4#\$!W	!				172 (65.6%)	
G-4#\$!I	!				90 (34.4%)	
G-4#\$7!\<_	!				#!	!
Day 7	!	(p=0.021 vs HA) (n/s vs spiro)	(p=0.015 vs spiro)	(n/s vs no-spiro)		0.021
G-4#\$!W	!				()4!+,)\$'!	!
G-4#\$!I	!				%*!+*\$4!	!
G-4#\$7!\<_	!				#!	!
vs!C4&!^ %p-=4:9\$)!					'' !#\$###%!	!
Day 14	!	(n/s vs HA) (n/s vs spiro)	(n/s vs spiro)	(n/s vs no-spiro)		0.84 !
G-4#\$!W	!				(&#!+, ,\$(!</td><td>!</td></tr><tr><td>G-4#\$!I</td><td>!</td><td></td><td></td><td></td><td>(!+#\$2!</td><td>!</td></tr></tbody></table>	

.


medRxiv preprint doi: https://doi.org/10.1101/2020.10.05.20206870; this version posted October 6, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

G-4#\$7!\<_	!				#!	!
vs!C4&!^					'' !#\$###%!	
<i>vs</i> !C4a!^ % <i>p</i> -=4:9\$)!					! 11 .\$ 11.11.11 .70 !	:
<i>vs</i> !C4&!`					#\$(2!+/03.!	!
% <i>p</i> -=4:9\$)! Days 30 and 60	1	(n/s vs HA)	(n/s vs spiro)	(n/s vs no-spiro)		
)!		(n/s vs spiro)			·	·
G-4#\$!W		!			(&(!+%##!	/01!
G-4#\$!I	!				#!	/01!
G-4#\$7!\<_	!				#!	/01!
HA =	a	c; / = -	ca ; /a = -a	cab ; / = -	са	



<i>p-=</i> 4:9\$)! Day 30!						%\$#!+/03.!
		(n/s vs HÁ)	(n/s vs	(n/s vs no-spiro)	(n/s vs HÁ)	
	HA = a	(n/s vs spiro) c; / = -	$\frac{spiro)}{ca ; CI = c c}$	a	(n/s vs spiro)!	
	Та	14 a	a	a COVID-19	Da 0, 7, 14	
	a 30		a	(CT) a.B a	HA-	
		,	a	СТ	. N -HA a	
	а	а	aHA a	, Da 30. N		
	a	а				
	Та	15 a	CO	VID-19 a	, a	
	а	а	a . N 2'	70 a		
	а	a	COVID-19	a .		
	Ta 14. C					
Chest CT scan (% of	Overall females	Non-HA females	HA females (n = 67)	s Spironolac Users (tone Non-spiro) (non-HA	p-value (overal
lungs affected)	(n = 270)	(n = 195)	(1 07)	(n=8)	+ HA) (n = 262)	(over ur
Day 0!	<u>+</u>	\pm	±		+7!89:;1«.!	/01!
		!	(n/a vs spiro)			
		(p=0.015 vs HA) (n /a vs spiro)				
Day 7!	\pm	\pm	\pm	/01	+7!89:;1«.!	/01!
		(p=0.053 vs HA) (n /a vs spiro)	(n/a vs spiro)			
vs!C4&!^	!	(/01	!	!
% <i>p</i> -=4:9\$) Day 14!	<u>+</u>	<u>±</u>	<u>+</u>		+7!89:;1«.!	/01!
-						
			(n/a vs spiro)			






Disease progression	Overall	Non-HA	HA females	Spironolactone	p-value
outcomes	females	females	(n = 67)	Users ()	(overall)
	(n = 270)	(n = 195)		(n = 8)	
Brescia COVID-19	0!	0	0	0	%\$##!+/03.!
Respiratory Severity					
Scale (0-4)					
!					
Hospitalization	0!	0	0	0	%\$##!+/03.!
Mechanical ventilation	0!	0	0	0	%\$##!+/03.!
Noradrenaline/dopamine	0!	0	0	0	%\$##!+/03.!
Death	0!	0	0	0	%\$##!+/03.!
HA = a	c; / = -	ca ; CI = c c	a		

Discussion

The importance of an early diagnosis of COVID-19



a		COVID-19. T	a a	a a a
a a		а	•	
R a	a a	a a	а	a,
a a	a a	a a	a	a, (aa
). C a ,	a a		a a	a
a . E	a	a	, a a a	a a
a a ,a	a	а	a . M	,
a a		а	a a a	a .
Μ	a a	- :	a a a	a
, a a		а	a	a
a , a		а	а	a a a a
a .				
_				
T a	a a		COVID-19	a
a a a	COVID-19	a a		
. W	a	a	COVID-19	a a

The patient with COVID-19: characteri ation of the patients and the disease

Ba	a a	a		-HA a	HA
а	a HA a	a		BMI. T	
а	a a		а	a	
HA	a	.F ,		a HA(
a a a	, a a	a) a		a a,a	а
а		a .			
D	BMI	HA a	-HA a	a	a
	a ,a	a a		. C ,	
	a,	HA a		a a	
COVID-19	a -HA				

W	a		a	а		
,	a a a				-HA	a,
	a PCOS				a	a
HA.						
I a	a a	a a		а,		а
a	(23-26)			а		
a a		a 80% a			a a-a	a
а,		, URTI-, a	GI	-	а	а
	, a			,	а	l
		а	а	HA a		
а	a a			а	а.	
т						
		a a a		, COVID		
a a			a		19 0	a
	, a			a		а
	aaa a					a
a a -		a,a a				a
versus		,		,		
С	, a	a a			a	а
а	a a a	, a	а	а		
T a	aa, a	Xa a	а	a a	, a	
	а		a	,	COVID-1	9 a
-	a per se. V a	D, a a		,	a a	С,
	а	a a	. H	,	a	а
		а				•

COVID-19 outcomes

COVID-19 PCR-А а а а , SAR-C V-2 a а a a а а а HA--HA, HA, a а . Н а -- -,

а	а	а	HA	4-	a	. Н	,		а	
а	а	l	COVID-19	a		а			a	
а			, a	COVID-1	9	а		а		HA-
	а	а		- a		a	a	•		

U	HA-	,		-	- a	а	а				a	
-HA a	HA	a,			а		a	а,	a	HA		a
-HA,		8	ı a	a	а	а		HA	a	а		a
	а											

А		а	a	а	а	а	а
,	HA-	а			,		a
a	aa a	а	а	-HA	a . T	a a	
		а	а	a	a	а	a.
I a	а,	а	а	a, a	a a		а,
a aa	a a	HA	а	а	а	a	,
a a a	a a	a a	AGA	(5,6,14,16,	17),	а	
TMPRSS-	2.						

	D	a		Da	0 a 7	HA
a	, a	а			a	
	, a		а	(Ta	11 13),	
а	a HA	a	,	á	a	
D			HA, a	a		а
a	a	а	a .			

	Т		а		a		a	a			a a	а
	а	а		а		а	а	а	а	14	a ,a	
а				а		а	- a	ı a			. A	1
HA	a						а	-HA a	HA-		а,	
	а			а	, a	a		а	a			

U	а	а	, a		а			
30	a a	а	а.Н	,	a a	а	а	а


			a	СТ	•	a		а	
a	а		. H	, a	а		а	a	а
а									
	С	a		а	COVID-19		, V	WHO COVID S a	а
В	a R	а	Sa,	а	a a			aa,	
	a			а	а	,	a a	, a	
Ι	а,		а						

0 HA a , HA a а а а -COVID-19. A а а а а, а COVID-19 a а а а а . S а а а a a а , COVID-19, а а 2 (ACE2) a а - -a a а а , TMPRSS2 a (AT) 2- -AT1 a , а а , a а (20-22), a а а а а а а a a a a •

Post-COVID syndrome?

	Т	а		а	а	a CO	OVID-19	
a		а	ıa,	a a	a	,aa,	а	
	- ,	-		,	а	-COVID	, a	а
		a	a 20	30% a	, a	а	,	a,
	а,	а,	a a	a a	а	, a	a	,
		а		(CFS),	а	a		а
a	a	(27,28).	Н,	a	a a	a		
	,	a		â	a,	a	а	a
а	a	a a						

The effect of specific treatments on COVID-19: comparison with existing literature



Limitations

A a а а а а -RCT, a а a a aa,a а а a a a a а . A а а а , , . H а а а а а , COVID-19 а а RCT a a а а а -, .

Т а а a а а COVID-19 а а а а : 1. La а а а а а а, a a COVID-19 ; 2. а а а а а а S COVID-19; 3. I a а а _ COVID-19, ; a 4. C а COVID-19 а а а , . A а а а а а , а а, а а а .


Final discussion

	S	COVID-19	а	,	, a	а	а	a , a
		a aa	а	а			a a a	
		а	a aa	,	а	a,		
	a							
	Т	a	a a	а		а	a a	,
		, a	a a			а		
		COVID-19,	a		a.			
	А	а,	HA	a a	a	а	COVID-19	,
а			а	а	a a			
	а	-HA a	а		Т		a	а
a		100	HA a				a, a	
			-HA. T	а		а	a a	
	а		AGA a		a	а	а,	

Conclusion

	А	, a		COVID	-19	a a	a a	aa a	
	а	a		а		a a	, a	а	
		, 8	a a			a	а		
		а			а	а	а		
а	а	a a		а	C	COVID-	19	,	
а	а			a a					
W		a -	а	(-HA), HA	a	a a	a	
		a	а,				COVIE	D- 19 a	
	a	a	а	а	a.	S	a	a a	
a	а	HA	۱.						

F а



References

- 1. G a W, N Z, H Y, a.C a aa a a 2019 C a. *N Engl J Med* 2020; F 28.
- 2. Ha a a a K, K a S, N С, а.О а а COVID-19: A a Ea Da a F N Y C [, 2020 Ma 29]. Obesity (Silver Spring). a a 2020;10.1002/ .22923.
- F, M a EK, a A a O 3. Ka M, Sa D a S a Pa COVID-19 [a a , 2020 A 30]. Obesity (Silver Spring). 2020;10.1002/ .22859.
- 4. Pa a L, K DG, L W, a. S , a a а а а -, a а а а - a COVID-19 В, a,a a Ν Y [a a , 2020 Ma 16]. *Metabolism*. 2020;108:154262.
- 5. Ca a a AB, Za FG, R a RG, A LCP, V a VC, A A, Da a LP, Ma a A, Ka a -D a L, L a T, J a DLM, Ba E S a PGM, T a a L, A -S a EO, La a a LN, S a AT, E LS, P a AJ, F a FGR, G a a OCE, Da a VCS, F a RHM, M a EP, G NA, Ca FF, Ma a IS, H a F CR, K а APM, A a a RB, B O a MF, S a-N A, Fa a a M, L

 RD, Ma a
 FR, B
 a
 O; C a
 C
 -19 B a
 I I
 a
 .

 H
 A
 M
 --M
 a C

 19.
 N
 E
 J
 M
 .
 2020
 J
 23:NEJM a2019014.
 :

 10.1056/NEJM a2019014.
 .
 .
 .
 .
 .
 .
 .

 7.
 La SA, Ga KH, B Q, a. T I a P C a D a

 2019 (COVID-19) F P R C Ca : E a a

 A a [
 a a
 , 2020 Ma 10]. Ann Intern Med.

 2020;10.7326/M20-0504.

8. W C, C X, Ca Y, a. R Fa A a W A R a
D S a Da Pa W C a D a 2019 P a
W a, C a [a a , 2020 Ma 13]. JAMA Intern Med.
2020;10.1001/a a .2020.0994.

9. W C, C X, Ca Y, a. R Fa A a W A R a
D S a Da Pa W C a D a 2019 P a
W a, C a [a a , 2020 Ma 13]. JAMA Intern Med.
2020;10.1001/a a .2020.0994.

10. :// . . / a / a - a - a - a - / -19/ a aa (La a S 29, 2020)

11. :// . . / a /2019- / / a- a -

a a - a . (La a S 29, 2020)

12. S EK, Za a LD, A KN, a. C a D a 2019 Ca S a - U Sa, Ja a 22-Ma 30, 2020. MMWR M M a W R 2020; 69:759.

 13. Ca a , F.A. R
 COVID-19: a

 . BMC Endocr Disord 20, 149 (2020).
 :// . /10.1186/ 12902-020

 00626-0

 14. Pa a a G, S a A, P C, B F, D B R, C a F, S a a a S,

 A FE. COVID-19 a a a a a : a .JI M .

 2020 A ;288(2):192-206. :10.1111/ .13091.

A, Va -Ga a S, Wa CG, a. A a a : a 15. G a a COVID-19 a S a - A а а а COVID-19 ſ a a , 2020 A 16]. J a *Cosmet Dermatol.* 2020;10.1111/ .13443. G A, M C J, Wa CG, a. W a a 16. a aa COVID-19? A a a a [a a , 2020 A 1]. Dermatol Ther. 2020; 13365. B, R R, 17. M C J, Wa CG, H a S, Va -Ga S, G a F, C S a -V a S, I a RM, Ta MA, Ca a FA, M J, a NA, S a R G Va a P COVID-19 D a S a R, G A. A : A P L a S H a COVID-19 Ma Pa . J S E A a D a V . 2020 S 25. 18. Ka K, A MP, G TA, a.A a а а a D a 2019 (C -19) - a Da a С , - a . C I D 2020. 19. G A, Wa CG, H a S, M C J, Va -Ga S, G a F, C B, R R, S a -V a S, Ra PM, Ca a FA, K a M, T A, S a J, S a R. A -a a a a COVID-19 : 77 .JE A a D a V . а а 2020 S 25. : 10.1111/ .16953. COVID-19-20. Ca a FA. Ca а а ? A J P E а а M a . 2020 Ma 1;318(5):E587-E588. : 10.1152/a .00136.2020. 21. Ca a FA, Wa CG, G A.S a : A A -a a A -D Ta Ma P P A a N С a (SARS-C V-2) I A R a D S (ARDS) COVID-19. F M (La a). 2020 J 28;7:453. : 10.3389/ .2020.00453. 22. Ca a FA, G A, Wa CG. S a а SARS-C V-2: Ta a , a 2 (ACE2), a -а -а (RAAS). M H . 2020 J 16;143:110112. : 10.1016/. . .2020.110112. :// . a . / / a - a -2019- -19- a-23. <u>a</u> ? <u>R</u> =126981& = (La a S 29, 2020)

K GU, K MJ, Ra SH, L J, Ba S, J J, K SH. C a a a 24. a a COVID-19. C М Ι. a a a 2020 J ;26(7):948. 1-948. 3. : 10.1016/. . .2020.04.040. 25. L JR, C a-E a CM, D S a DR a . O a а а a a a a - - a а E a .E A a (COVID-19): a 0 . 2020 а A ;277(8):2251-2261. : 10.1007/ 00405-020-05965-1. 26. T JY, W A, Z D, Fa JH, TaT. TP O a а G a D COVID-19 Pa : A S а а R a Ma-

a a . O a H a N S . 2020 J ;163(1):3-11. : 10.1177/0194599820926473.

27. N a P. P COVID-19 а а а а a a a : , а Ν a S . 2020 D ;21:100276. : а а . 10.1016/. .2020.100276.

28. C a DJ, H W, C SP, F a MA. C a a a a COVID-19 a . Pa . 2020 A ;161(8):1694-1697. : 10.1097/. a .00000000001950.